Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease

Abstract Background Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruolin Li, Ming Ren, Yingxin Yu
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	6D11 Alzheimer's disease Aβ neurogenesis prion protein Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/cafe6ace1a4b4e5aa1e0069eb8f1fa22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cafe6ace1a4b4e5aa1e0069eb8f1fa22
record_format	dspace
spelling	oai:doaj.org-article:cafe6ace1a4b4e5aa1e0069eb8f1fa222021-11-25T06:06:36ZAnti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease2162-327910.1002/brb3.2365https://doaj.org/article/cafe6ace1a4b4e5aa1e0069eb8f1fa222021-11-01T00:00:00Zhttps://doi.org/10.1002/brb3.2365https://doaj.org/toc/2162-3279Abstract Background Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis of AD. Targeting this pathway is a new idea for the treatment of the disease. A recent study reveals that the cellular prion protein (PrP), a receptor for Aβ oligomers, regulates neurogenesis, and its elevated expression is related to cell differentiation. The aim of the present study was to investigate the neuroprotective effects of 6D11 (PrP monoclonal antibody) via neurogenesis promotion in APP/PS1 transgenic mice and Aβ‐induced cell model of AD. Methods In the present study, 9‐month‐old male APP/PS1 mice were injected with 6D11. Then, the Morris water maze was used to examine the spatial learning and memory abilities of the mice in both groups, and immunostained was used to assess the level of Aβ, neurogenesis, and neural stem cells (NSCs) differentiation. Results 6D11 attenuated cognitive deficits in APP/PS1 transgenic mice, which was accompanied by a decrease of the deposition of Aβ. In addition, 6D11 treatment promoted differentiation of the existing hippocampal cells to neurons. Conclusions Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Aβ‐induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Aβ peptide signal.Ruolin LiMing RenYingxin YuWileyarticle6D11Alzheimer's diseaseAβneurogenesisprion proteinNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain and Behavior, Vol 11, Iss 11, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	6D11 Alzheimer's disease Aβ neurogenesis prion protein Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	6D11 Alzheimer's disease Aβ neurogenesis prion protein Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Ruolin Li Ming Ren Yingxin Yu Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
description	Abstract Background Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis of AD. Targeting this pathway is a new idea for the treatment of the disease. A recent study reveals that the cellular prion protein (PrP), a receptor for Aβ oligomers, regulates neurogenesis, and its elevated expression is related to cell differentiation. The aim of the present study was to investigate the neuroprotective effects of 6D11 (PrP monoclonal antibody) via neurogenesis promotion in APP/PS1 transgenic mice and Aβ‐induced cell model of AD. Methods In the present study, 9‐month‐old male APP/PS1 mice were injected with 6D11. Then, the Morris water maze was used to examine the spatial learning and memory abilities of the mice in both groups, and immunostained was used to assess the level of Aβ, neurogenesis, and neural stem cells (NSCs) differentiation. Results 6D11 attenuated cognitive deficits in APP/PS1 transgenic mice, which was accompanied by a decrease of the deposition of Aβ. In addition, 6D11 treatment promoted differentiation of the existing hippocampal cells to neurons. Conclusions Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Aβ‐induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Aβ peptide signal.
format	article
author	Ruolin Li Ming Ren Yingxin Yu
author_facet	Ruolin Li Ming Ren Yingxin Yu
author_sort	Ruolin Li
title	Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
title_short	Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
title_full	Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
title_fullStr	Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
title_full_unstemmed	Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease
title_sort	anti‐prp monoclonal antibody as a novel treatment for neurogenesis in mouse model of alzheimer's disease
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/cafe6ace1a4b4e5aa1e0069eb8f1fa22
work_keys_str_mv	AT ruolinli antiprpmonoclonalantibodyasanoveltreatmentforneurogenesisinmousemodelofalzheimersdisease AT mingren antiprpmonoclonalantibodyasanoveltreatmentforneurogenesisinmousemodelofalzheimersdisease AT yingxinyu antiprpmonoclonalantibodyasanoveltreatmentforneurogenesisinmousemodelofalzheimersdisease
_version_	1718414190680473600

Anti‐PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease

Ejemplares similares